InnoCare Pharma’s ICP-490 Receives NMPA Approval for Hematological Malignancies
Beijing InnoCare Pharma (HKG: 9969) announced that it has received clinical trial approval from the...
Clinical trial approval / initiation
PersonGen BioTherapeutics’ TAA06 Receives Clinical Trial Approval for B7-H3 CAR-T Therapy
The Center for Drug Evaluation (CDE) website indicates that PersonGen BioTherapeutics (Suzhou) Co., Ltd’s TAA06,...
Arctic Vision Enrolls First Patient in ARVN003 Phase III Trial for Presbyopia
China-based ophthalmic therapies developer Arctic Vision announced the first patient enrollment in a Phase III...
JW Therapeutics Initiates Phase I Study of JWATM204 for Hepatocellular Carcinoma
China-based JW Therapeutics (HKG: 2126) announced the initiation of a Phase I clinical study for...
Junshi Biosciences Receives FDA Approval for PI3K-α Inhibitor RP903 in Breast Cancer Study
China’s Junshi Biosciences (HKG: 1877, SHA: 688180) announced that it has received approval from the...
Abbisko Therapeutics Doses First Patient in ABSK061 Phase I Study for Solid Tumors
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) announced the first patient dosing in a...
Jixing Pharmaceuticals Enrolls First Patient in Etripamil Phase III Study for PSVT
China-based Ji Xing Pharmaceuticals Ltd (Jixing) announced the first patient enrollment in a Phase III...
Ascentage Pharma’s APG-5918 Receives FDA Approval for First-in-Human Study
Suzhou-based Ascentage Pharma (HKG: 6855) announced that it has received approval from the US Food...
Humanwell Healthcare Wins NMPA Approval for RFUS-144 in Pain Management
China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) announced receiving approval from the National Medical...
Eli Lilly’s Donanemab Receives Tacit Approval for Alzheimer’s Clinical Trial in China
The Center for Drug Evaluation (CDE) website indicates that US major Eli Lilly’s (NYSE: LLY)...
Recbio’s R520A mRNA COVID-19 Vaccine Receives Clinical Approval in the Philippines
China-based Jiangsu Recbio Technology Co., Ltd has announced receiving clinical trial approval from the Food...
Harbour BioMed Receives FDA Approval for HBM7008 Clinical Trials
China-based Harbour BioMed (HKG: 2142) has announced receiving clinical trial approval from the US FDA...
Cosunter Pharma’s HBV Surface Antigen Inhibitor GST-HG121 Approved for Phase I Trial
China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced receiving approval from the ethics...
Antengene Receives Australian TGA Approval for ATG-018 Clinical Trial
China-based biopharma Antengene Corporation (HKG: 6996) has announced receiving approval from the Therapeutic Goods Administration...
Jumbo Drug Bank’s JDB153 Enters Phase I Trial for Advanced Solid Tumors
Data from Fineline Cube indicates that JDB153, a potential first-in-class (FIC) small-molecule inhibitor targeting Mnk...
RemeGen’s Telitacicept Begins Global Phase III Trial for Severe SLE
China-based pharmaceutical firm RemeGen (HKG: 9995) has announced the first patient dosing in a global...
InnoCare Pharma’s ICP-189 First Dosed in China SHP2 Inhibitor Trial
Beijing InnoCare Pharma (HKG: 9969) has announced the first patient dosing in a clinical study...
InnoCare and Keymed Biosciences’ CCR8-Targeted mAb CM369 Accepted by NMPA
China-based InnoCare (HKG: 9969) and Keymed Biosciences Inc. (HKG: 2162) announced that an Investigational New...
Henlius Biotech Begins Global Phase III Trial for Denosumab Biosimilar HLX14
China-based Shanghai Henlius Biotech Inc. (HKG: 2696) has announced the first patient dosing in a...
Cellular Biomedicine Group’s C-CAR039 Receives NMPA Approval for B-Cell NHL Study
China-based Cellular Biomedicine Group Inc. (CBMG), a private company following a merger deal in February...